Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100 India
T 91 80 2808 2808
F 91 80 2852 3423

www.biocon.com

Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/19
January 22, 2014

The National Stock Exchange of India Limited
Exchange Plaza
Bandra – Kurla Complex
Bandra (East)
Mumbai- 400 051

"By Email & Courier"

Kind Attn: **Mr. Hari K.**

Subject: Intimation of Press Release

Please find the enclosed two press releases made by the Company, on the following topics:

- **"Biocon Collaborates with Advaxis for 'ADXS-HPV', a novel cancer immunotherapy"**
- **"Kiran Mazumdar-Shaw to receive 2014 Othmer Gold Medal from Chemical Heritage Foundation"**

Kindly take this intimation on record.

Thanking you.

Yours faithfully,
For Biocon Limited,

Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
M: +91 9945315151
T: +91 80 2808 2037

By Fax to NSE: 022 – 2659 8237 / 38
By Email to NSE: cmlist@nse.co.in

Press Release

Biocon Collaborates with Advaxis for 'ADXS-HPV' A Novel Cancer Immunotherapy

Bangalore, India and Princeton, New Jersey – January 22, 2014

Biocon Ltd., (BIOCON.BO), Asia's premier biotechnology company, and Advaxis, Inc., (NASDAQ: ADXS), a leader in developing the next generation of cancer immunotherapies, announced today that they have entered into an exclusive licensing agreement for co-development and commercialization of **ADXS-HPV**, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)-associated cervical cancer in women, for India and key emerging markets.

As per the agreement, Biocon will also have access to Advaxis' innovative and proprietary immunotherapy technology that can be leveraged for the development of other novel therapeutics for various unmet medical needs.

Chairperson and Managing Director of Biocon, Kiran Mazumdar-Shaw said, *"Biocon is committed to finding solutions for women's health issues. This partnership will enable us to develop **ADXS–HPV** a novel immunotherapy to combat cervical cancer in women. It is a promising technology that has the ability to suppress the tumor inside the micro-environment, and can be leveraged for developing several other novel therapeutics to address various unmet medical needs of patients in India and other emerging markets."*

"We are excited to partner with Biocon, one of the world's leading biotechnology companies and the largest biotechnology company in India to bring our innovative cancer immunotherapy for cervical cancer to women with few alternatives," commented **Daniel J. O'Connor, Chief Executive Officer of Advaxis.** *"This agreement gives us reach into key markets where the number of patients with HPV-associated cancers is overwhelming."*

Dr. Abhijit Barve, President of Research & Development at Biocon said, *"The clinical data generated so far with **ADXS-HPV** look very encouraging in patients with advanced metastatic disease who were resistant or refractory to existing therapies. The clinical responses were comparable to prevalent chemotherapy agents and this was achieved*

*with very low incidence of adverse events. Hence **ADXS-HPV** is likely to offer patients a safe and effective alternate to chemotherapeutic agents."*

Cervical cancer is one of the most frequent cancers in women in India. Over 366 million women of the age of over 15 years, are at a risk of developing cervical cancer. It is estimated that every year over 134,000 women are diagnosed with cervical cancer in India and nearly 73,000 die from this disease. Approximately 7.9% of women in general are estimated to harbor cervical HPV infection at a given time, and 82.5% of invasive cervical cancers are attributed to high-risk HPV strains.*

According to WHO, in 2008, there were over 530,000 new cases of cervical cancer worldwide, 90% of these were reported in developing countries. While globally there were over 300,000 deaths, the African region recorded over 50,000 deaths and Asian countries reported over 150,000 deaths for the year.

ADXS-HPV has the potential to address this huge challenge in the developing world.

Under the terms of the agreement, Advaxis will provide exclusive commercialization rights for **ADXS-HPV** to Biocon for India, and key emerging markets for all HPV-associated cancers. Advaxis will manufacture and supply **ADXS-HPV** to Biocon.

**Source:* *WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) 2010.*

About Biocon Limited

Established in 1978, Biocon Limited, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN(R), Glargine, BASALOG®, India's first biologic BioMAb-EGFR ® for head and neck cancer and world's first biosimilar trastuzumab, CANMAb™. It has also successfully developed its second novel biologic Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as ALZUMAb™ for psoriasis in India. www.biocon.com

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis' immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.

ADXS-HPV, Advaxis' lead immunotherapy for the treatment of HPV-associated cancers, has improved survival and objective tumor responses in patients with recurrent cervical cancer. **ADXS-HPV** has Orphan Drug Status for both anal and head and neck cancers. As part of its global commercialization strategy to enter into regional licensing deals with other market dominant biopharmaceutical companies in territories where there is a high prevalence of HPV-associated cancers, Advaxis has granted an exclusive license for the development and commercialization of **ADXS-HPV** in Asia.

ADXS-cHER2 is an immunotherapy for the treatment of HER2 overexpressing cancers (such as breast, gastric, and other cancers in humans and for osteosarcoma in canines). Advaxis' lead animal-health immunotherapy, ADXS-cHER2, has demonstrated encouraging survival data in a Phase 1 trial in canine osteosarcoma. These data provide the rationale to advance this same immunotherapy into a Phase 1 clinical trial in women with HER2-positive breast cancer. The Company is preparing to submit an IND for ADXS-cHER2 in breast cancer in 2014.

Advaxis has created over 15 distinct immunotherapies based on its platform either directly or through strategic collaborations with recognized centers of excellence such as: the University of Pennsylvania, Brown University, the Georgia Regents University Cancer Center, the Icahn School of Medicine at Mount Sinai, and others.

For more information please visit www.advaxis.com or connect with us on Facebook, Twitter, Google+ and LinkedIn.

Disclaimer

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our

company, our directors, nor any of our affiliates, have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

For further information:	
Biocon Media Contacts **Seema Ahuja** Head-Corporate Communications T: +91-80-2808-2222, M:+919972317792 Email: seema.ahuja@biocon.com	**Rumman Ahmed** Manager-Corporate Communications T: +91-80-2808-2223, M:+919845104173 Email: rumman.ahmed@biocon.com
Biocon: Investors Contact Saurabh Paliwal Head Investor Relations +91 95383 80801 saurabh.paliwal@biocon.com	**Advaxis, Inc** Lisa Caperelli Senior Director of Investor Relations and Corporate Communications caperelli@advaxis.com 215.206.1822

Biocon

Press Release

Kiran Mazumdar-Shaw to Receive 2014 Othmer Gold Medal from Chemical Heritage Foundation

Bangalore, India, January 22, 2014

Biocon Ltd, Asia's premier biotechnology company, announced today that its Chairperson and Managing Director, Kiran Mazumdar-Shaw, will be conferred the 2014 Othmer Gold Medal – the top award of U.S.-based Chemical Heritage Foundation.

The Chemical Heritage Foundation, located in Philadelphia, is a collections-based nonprofit organization that preserves the history and heritage of chemistry, chemical engineering, and related sciences and technologies. The collections are used to create a body of original scholarship that illuminates chemistry's role in shaping society.

Acknowledging Ms Shaw's outstanding contribution to the Indian Biotech sector, **Carsten Reinhardt, President and CEO, Chemical Heritage Foundation said,** *"Kiran Mazumdar-Shaw was the first woman to become a brew master in India. Then she used her knowledge of fermentation to become one of the greatest entrepreneurs in the history of her nation. In addition to her great success in business, she is among the world's leading philanthropists. She has devoted much of her personal fortune to providing healthcare to the poorest people in her country and to many other philanthropic projects."*

Ms. Mazumdar-Shaw will be the 20th recipient of the Othmer Gold Medal and the third woman to receive CHF's most coveted award. CHF established the Othmer Gold Medal in 1997 to honor outstanding individuals who have made multifaceted contributions to chemical and scientific heritage through outstanding activity in such areas as innovation, entrepreneurship, research, education, public understanding, legislation, or philanthropy.

Expressing her delight, **Ms Kiran Mazumdar Shaw, Chairperson Biocon, said,** *"I am honoured to receive this prestigious honour and join the distinguished list of previous recipients like James Watson, Ahmed Zawail, Robert Langer and many others from whom I have drawn great inspiration and deeply admired".*

Under Ms. Mazumdar Shaw's stewardship Biocon has evolved into India's largest biotech company committed to innovation and affordability to deliver world class therapeutics to patients across the globe.

A pioneer of the biotechnology industry in India, Ms. Mazumdar Shaw has made her country proud with a globally recognized bio-pharma enterprise - Biocon.

About the Othmer Gold Medal

The medal is presented annually and cosponsored by CHF and four affiliated organizations: the American Chemical Society (ACS), the American Institute of Chemical Engineers (AIChE), the Chemists' Club, and the Société de Chimie Industrielle. The medal commemorates Donald Othmer (1904–1995), noted researcher, consultant, editor, engineer, inventor, philanthropist, professor, and coeditor of the *Kirk-Othmer Encyclopedia of Chemical Technology*.

Previous honorees of the Othmer Gold Medal are John D. Baldeschwieler, Arnold O. Beckman, Ronald C. D. Breslow, Thomas Cech, Carl Djerassi, Marye Anne Fox, Mary Lowe Good, Harry B. Gray, George S. Hammond, Jon M. Huntsman, Kazuo Inamori, Ralph Landau, Robert S. Langer, Yuan Tse Lee, Gordon E. Moore, P. Roy Vagelos, James D. Watson, George Whitesides, and Ahmed Zewail.

For further information	
Media Contacts	
Seema Ahuja Head-Corporate Communications +91 9972317792 seema.ahuja@biocon.com	**Rumman Ahmed** Manager-Corporate Communications M: +91 9845104173 rumman.ahmed@biocon.com